Table 2.
The impact of different factors on VISTA mRNA level. Clinical characteristics of the group considered 35 patients with mRNA.
| Clinical Factor | p | |||||
|---|---|---|---|---|---|---|
| N (%) | ||||||
| Sex | Female | 13 (37.1) | 0.35 | |||
| Male | 22 (62.7) | |||||
| Median (range) | ||||||
| Age | 60 (30–90) | 0.56 | ||||
| 0 = no, 1 = yes (%), NA = not available | ||||||
| Radiotherapy | 0: 18 (51.4) | 1: 15 (42.9) | NA: 2 (5.7) | 0.59 | ||
| Chemotherapy | 0: 30 (85.7) | 1: 3 (8.6) | NA: 2 (5.7) | 0.51 | ||
| Surgical resection | 0: 7 (20.0) | 1: 28 (80.0) | 0.56 | |||
| (1–3):N(%) | ||||||
| Grade | 1: 19 (54.3) | 2: 13 (37.1) | 3: 3 (8.6) | 0.98 | ||
| (1–4):N(%) | ||||||
| AJCC Stage | 1: 10 (28.6) | 2: 10 (28.6) | 3: 4 (11.4) | 4: 11 (31.4) | 0.73 | |
| T (1–4):N(%), N (0–3):N(%) | ||||||
| Classification | T | 1: 6 (17.1) | 2: 15 (42.9) | 3: 8 (22.9) | 4: 6 (17.1) | 0.86 |
| N | 0: 14 (40.0) | 1: 4 (11.4) | 2: 15 (42.9) | 3: 2 (5.7) | 0.86 | |
For the group of patients, p-value was estimated to find any significant difference in VISTA expression level according to Grade, AJCC Stage, T and N classifications with the one-way ANOVA test, and according to other parameters with Student’s t-test.